NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
30.41
-2.42 (-7.39%)
At close: Mar 3, 2026, 4:00 PM EST
31.48
+1.07 (3.54%)
Pre-market: Mar 4, 2026, 6:31 AM EST
NAMS Employees
NewAmsterdam Pharma Company had 100 employees as of December 31, 2025. The number of employees increased by 32 or 47.06% compared to the previous year.
Employees
100
Change
32
Growth
47.06%
Revenue / Employee
$225,030
Profits / Employee
-$2,038,190
Market Cap
3.50B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 100 | 32 | 47.06% |
| Mar 31, 2025 | 77 | 37 | 92.50% |
| Dec 31, 2024 | 68 | 39 | 134.48% |
| Sep 30, 2024 | 62 | 40 | 181.82% |
| Jun 30, 2024 | 57 | 35 | 159.09% |
| Mar 31, 2024 | 40 | 23 | 135.29% |
| Dec 31, 2023 | 29 | 12 | 70.59% |
| Jun 30, 2023 | 22 | - | - |
| Dec 31, 2022 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Corcept Therapeutics | 730 |
| ADMA Biologics | 685 |
| ACADIA Pharmaceuticals | 654 |
| Crinetics Pharmaceuticals | 594 |
| Xenon Pharmaceuticals | 370 |
| Alumis | 223 |
| Centessa Pharmaceuticals | 114 |
NAMS News
- 6 days ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - GlobeNewsWire
- 13 days ago - NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 25 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 7 weeks ago - NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - GlobeNewsWire
- 3 months ago - NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating - Seeking Alpha